Wedbush Maintains Neutral on Praxis Precision Medicine, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has maintained a Neutral rating on Praxis Precision Medicine (NASDAQ:PRAX) while raising the price target from $16 to $29.

January 12, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Praxis Precision Medicine but increases the price target from $16 to $29.
The increase in price target by a reputable analyst suggests a positive outlook on the company's value, which could lead to increased investor interest and a potential short-term rise in the stock price. However, the Neutral rating indicates that the analyst believes the stock may already be fairly valued at its current price, which tempers the potential impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100